Humana posted $32.65 billion in revenue and $134 million in net income for Q3 2025, with Adjusted EPS of $3.24. The company maintained its adjusted EPS guidance for FY2025 and noted strong performance in CenterWell and Medicaid services.

Humana delivered strong Q2 2025 performance, with $32.39B in revenue and $741M in net income. The company raised its full-year adjusted EPS and revenue outlook, driven by CenterWell growth and confident pricing strategy despite expected Medicare Advantage membership declines.

Humana delivered a solid Q1 2025 performance, driven by strong results in its Medicare Advantage business and continued execution of its long-term value-based care strategy.

Humana reported a net loss per share of $5.76 on a GAAP basis and an adjusted net loss per share of $2.16 for Q4 2024. The company generated $29.21 billion in revenue during the quarter, with an adjusted revenue of $29.20 billion. Operating income saw a significant decline, primarily due to impairment charges and value creation initiatives.

Humana reported a GAAP EPS of $3.98 and an adjusted EPS of $4.16 for Q3 2024. The company updated its full-year 2024 EPS guidance to at least $12.89 on a GAAP basis and at least $16.00 on an adjusted basis. Humana also raised its 2024 individual Medicare Advantage annual membership growth expectation.

Humana reported a solid second quarter with a GAAP EPS of $5.62 and an adjusted EPS of $6.96. The company has revised its full-year GAAP EPS guidance to approximately $12.81 while affirming its Adjusted EPS guidance of approximately $16.00. Humana is raising its 2024 individual Medicare Advantage annual membership growth to approximately 225,000, or 4.2 percent.

Humana reported its Q1 2024 financial results, with a GAAP EPS of $6.11 and an adjusted EPS of $7.23. The company has revised its full-year 2024 EPS guidance on a GAAP basis but affirmed its adjusted EPS guidance. They also raised their individual Medicare Advantage annual membership growth expectations.

Humana reported a net loss per share of $4.42 on a GAAP basis and an adjusted loss per share of $0.11 for the fourth quarter of 2023. The results were impacted by rising Medicare Advantage medical costs. The company provided initial full-year 2024 EPS guidance of approximately $14.87 on a GAAP basis and approximately $16.00 on an adjusted basis.

Humana reported Q3 2023 GAAP EPS of $6.71 and adjusted EPS of $7.78. The company is revising its FY 2023 GAAP EPS guidance to at least $26.31, while affirming its adjusted EPS guidance of at least $28.25. Individual Medicare Advantage membership growth is expected to be approximately 860,000, a 19% increase year-over-year.

Humana reported a strong second quarter with an Adjusted EPS of $8.94 and affirmed its full year 2023 Adjusted EPS guidance of at least $28.25. The company's individual Medicare Advantage business is expected to grow by approximately 825,000 members in 2023, reflecting an 18 percent growth rate.

Humana reported a strong start to the year with better-than-expected first-quarter results, driven by robust membership growth and favorable inpatient utilization trends in the individual Medicare Advantage business. The company increased its full-year 2023 adjusted EPS guidance by $0.25 to at least $28.25 and affirmed strong individual Medicare Advantage membership growth of at least 775,000, or 17.0 percent growth over FY 2022.

Humana reported its Q4 2022 financial results, with a GAAP loss per share of $0.12 and an adjusted EPS of $1.62. The company announced FY 2023 EPS guidance of at least $27.57 on a GAAP basis and at least $28.00 on an Adjusted basis. Humana completed realignment into two segments, Insurance and CenterWell.

Humana reported a strong third quarter with GAAP EPS of $9.39 and Adjusted EPS of $6.88. The company affirmed its full year 2022 Adjusted EPS guidance of approximately $25.00, representing 21% growth over FY 2021.

Humana reported a strong second quarter with adjusted EPS of $8.67, representing 26% growth over the prior year. The company raised its full-year adjusted EPS guidance to approximately $24.75, reflecting a compelling 20% growth. The outperformance was driven by better-than-anticipated medical cost trends and lower-than-anticipated administrative costs.

Humana reported a strong start to the year with all business lines performing well. The company raised its full year Adjusted EPS guidance to approximately $24.50, representing 19 percent growth over the actual 2021 results. Humana is also making progress in improving Medicare Advantage membership growth in 2023.

Humana reported a loss per common share of $0.11 on a GAAP basis and an adjusted EPS of $1.24 for the fourth quarter of 2021. The company's core operations remain strong, driven by its Medicare Advantage business and Healthcare Services lines. Humana commits to drive $1 billion of additional value for the enterprise through cost savings, productivity initiatives, and value acceleration from previous investments to create capacity to fund growth and investment in the Medicare Advantage business and further expansion of Healthcare Services capabilities.

Humana Inc. reported strong third-quarter results, with GAAP earnings per diluted common share of $11.84 and adjusted earnings per share of $4.83. The company revised its full-year 2021 EPS guidance to approximately $23.67 on a GAAP basis, or approximately $20.50 on an Adjusted basis.

Humana reported a GAAP EPS of $4.55 and an adjusted EPS of $6.89 for Q2 2021. The company maintains its full-year 2021 adjusted EPS financial guidance and reaffirms its expected individual Medicare Advantage membership growth range.

Humana reported a strong start to the year with solid results across the company's segments, fueled by Medicare Advantage and state-based membership growth. The company reaffirms its full-year adjusted EPS financial guidance.

Humana reported a loss per common share of $2.07 on a GAAP basis and $2.30 on an Adjusted basis for Q4 2020. The company's results were impacted by COVID-19 treatment and testing costs, crisis relief efforts, strategic investments, and increased marketing expenses. Humana announced FY 2021 EPS guidance in a range of $20.82 to $21.32 on a GAAP basis, $21.25 to $21.75 on Adjusted basis.

Humana's Q3 2020 earnings were impacted by increasing utilization, COVID-19 testing and treatment costs, and crisis relief efforts. The company reported GAAP EPS of $10.05 and Adjusted EPS of $3.08. Humana anticipates fourth quarter losses to reflect continued support for its constituents, along with the impact of increasing utilization, and COVID-19 testing and treatment costs.

Humana reported a strong second quarter with EPS of $13.75 on a GAAP basis and $12.56 on an adjusted basis. The company reaffirmed its FY 2020 Adjusted EPS guidance range of $18.25 to $18.75 and increased full year expected individual Medicare Advantage membership growth.

Humana reported a strong first quarter with GAAP EPS of $3.56 and Adjusted EPS of $5.40. The company reaffirmed its FY 2020 Adjusted EPS guidance range of $18.25 to $18.75 and increased its full year expected individual Medicare Advantage membership growth.

Humana's Q4 2019 earnings exceeded expectations, driven by strong performance in the Medicare Advantage business and Healthcare Services segment. The company reported a GAAP EPS of $3.84 and an adjusted EPS of $2.28. Revenues for the quarter were $16.295 billion. The company also provided FY 2020 EPS guidance in a range of $17.76 to $18.26 on a GAAP basis, $18.25 to $18.75 on an Adjusted basis.